Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PhoreMost, Otsuka ink agreement
March 2020
SHARING OPTIONS:

CAMBRIDGE, U.K.—PhoreMost Limited and Otsuka Pharmaceutical Co. have launched a multi-project collaboration centered on drug discovery. Though financial details for the agreement were not released, the companies reported that the collaboration will consist of PhoreMost applying its SITESEEKER next-generation phenotypic screening platform against disease-relevant pathways nominated by Otsuka. The latter company will validate and characterize any identified targets as part of its internal development pipeline, with an initial focus on the targets’ gene therapy applications. SITESEEKER screens for protein shape diversity by using proprietary protein interference technology to scan the proteome for novel, druggable targets, which results in the discovery of functionally active peptides.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.